The downgrade by Leerink Partners from Outperform to Market Perform, coupled with a drastic reduction in the price target from $12 to $4, is a strong negative signal to the market. This suggests a reassessment of CureVac's valuation and future prospects by analysts, likely leading to a decrease in investor confidence and a short-term negative impact on the stock price.